Genentech Inc-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013500)
◆英語タイトル:Genentech Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013500
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:104
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Genentech Inc (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that develops and markets medicines to address serious medical needs. Its clinical development pipeline includes alectinib and Erlotinib for metastatic non-small cell lung cancer; Anti-ST2 for asthma; etrolizumab for ulcerative colitis; atezolizumab for solid tumors and metastatic melanoma; obinutuzumab for non-Hodgkin’s lymphoma; and pertuzumab for breast cancer, among others. Genentech develops drugs in several therapeutic areas including oncology, immunology, neuroscience, metabolism, infectious disease, ophthalmology and bioinformatics. The company has manufacturing facilities in Vacaville, South San Francisco and Oceanside, California. Genentech is headquartered in South San Francisco, California, the US.

Genentech Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Genentech Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Genentech Inc, Medical Devices Deals, 2011 to YTD 2017 13
Genentech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Genentech Inc, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Genentech Acquires NanoPrint LM60 Microarrayer Platform From Arrayit 17
Partnerships 18
Epizyme Enters into Agreement with Genentech 18
Inovio Pharma Enters into Agreement with Genentech 19
Amunix Operating Enters into R&D Agreement with Genentech 20
BioNTech Enters into Agreement with Genentech 21
Gradalis Enters into Agreement with Genentech 22
G1 Therapeutics Enters into Agreement with Genentech 23
Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 24
Charles River Laboratories International Extends Agreement with Genentech 25
BioLineRx Enters into Agreement with Genentech 26
Epizyme Enters into Agreement with Genentech 27
Astex Pharma Enters into Agreement with Genentech 28
Clovis Oncology Enters into Agreement with Genentech 29
Janssen Research & Development Enters into Agreement with Genentech 30
Kite Pharma Enters into Agreement with Genentech 31
PeptiDream Enters into Agreement with Genentech 32
Corvus Pharma Expands its Agreement with Genentech 33
Immune Design Enters into Clinical Trial Collaboration with Genentech 34
WaferGen Bio-systems Enters into Research Agreement with Genentech 35
23andMe Partners with Genentech 36
Genentech Enters into Research Agreement with NewLink Genetics 37
Argenta Discovery Extends Drug Discovery Agreement With Genentech 38
Ascendis Pharma Enters Into Collaboration Agreement with Genentech 39
RQx Pharma Enters Into Drug Discovery Agreement With Genentech 40
Ensemble Therapeutics Enters Into Drug Discovery Agreement With Genentech 41
Constellation Pharma Enters Into Co-Development Agreement With Genentech 42
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 43
Galena Biopharma Enters Into Co-Development Agreement With The Henry M. Jackson Foundation And Genentech 44
Argenta Discovery Extends Drug Discovery Agreement With Genentech 46
Array BioPharma Enters Into Co-Development Agreement With Genentech 47
Plexxikon Enters Into Co-Promotion Agreement With Genentech 49
Licensing Agreements 50
Dermira Enters into Licensing Agreement with F. Hoffmann-La Roche and Genentech for Lebrikizumab 50
Mylan Enters into Licensing Agreement with Genentech and Roche 52
Genentech Enters into Licensing Agreement with Novimmune 53
Genentech to Enter into Licensing Agreement with Hanmi Pharma 54
Denali Therapeutics Enters into Licensing Agreement with Genentech 55
Genentech Enters into Licensing Agreement with Nimbus Therapeutics 56
Genentech Expands Licensing Agreement with Arvinas 57
Phylogica Extends Licensing Agreement with Genentech 58
Genentech to Terminate its Licensing Agreement with NewLink Genetics for NLG919 59
Coherus BioSciences Enters into Licensing Agreement with Genentech 61
Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 62
Xenon Pharma Extends Licensing Agreement with Genentech 64
Novogen Enters into Licensing Agreement with Genentech for GDC-0084 65
Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 66
Genentech Enters into Licensing Agreement with Carmot Therapeutics 67
Genentech Enters into Licensing Agreement with Almac Discovery 68
Immunocore Enters Into Licensing And Research Agreement With Genentech For Cancer Drugs 69
Afraxis Enters Into Licensing Agreement With Genentech 70
AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 71
FORMA Therapeutics Enters Into Licensing Agreement With Genentech 73
Nerviano Medical Sciences Enters Into Licensing Agreement With Genentech 74
Spirogen Enters Into Licensing Agreement With Genentech 75
AMRI Enters Into Licensing Agreement With Genentech 76
Asset Transactions 77
Gilead Sciences Completes Acquisition Of Oceanside Clinical Plant From Genentech For US$28.3 Million 77
Acquisition 78
Noritsu Koki to Acquire 64.7% Stake in Genentech for USD27 Million 78
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology’s Spin-Out Companies 79
Genentech Inc – Key Competitors 80
Genentech Inc – Key Employees 81
Genentech Inc – Locations And Subsidiaries 82
Head Office 82
Other Locations & Subsidiaries 82
Recent Developments 83
Corporate Communications 83
Apr 13, 2016: Stand Up To Cancer Launches “Catalyst,” a New Research Program Supported by Industry 83
Legal and Regulatory 85
Jan 11, 2017: New Drug Formulary Will Help Expedite Use of Agents in Clinical Trials 85
Jan 09, 2017: Genentech withdraws counterclaim against Exelixis 86
Government and Public Interest 87
Jun 29, 2017: Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury 87
Product News 88
11/28/2016: Curis Announces Full Approval of Roche’s Erivedge® in the European Union 88
Oct 12, 2017: 10 SU2C Catalyst Clinical Trials Launched 89
09/05/2016: Novimmune Receives Milestone Payment from Collaboration with Genentech 91
06/15/2017: NICE reverses provisional decision and recommends Kadcyla (trastuzumab emtansine) for HER2-positive advanced breast cancer in England 92
06/12/2017: T-DM1 in HER2 Overexpressing, Amplified or Mutated Metastatic NSCLC 93
Product Approvals 95
Jun 15, 2017: Kadcyla new deal for breast cancer patients given green light in final draft guidance 95
Apr 10, 2017: Roche’s Kadcyla accepted for use in NHS Scotland 96
Dec 29, 2016: Kadcyla too expensive for routine funding on NHS 97
Clinical Trials 98
May 17, 2017: Data from Clinical Study of NewLink Genetics’ Navoximod to Be Presented at ASCO 2017 98
Apr 21, 2017: NewLink Genetics Provides Update on Pipeline Drug GDC-0919 at ASCO 99
Jul 07, 2016: AC Immune to receive milestone payment for Anti-Tau Antibody moving into Phase 1 trial for Alzheimer’s disease 100
Jun 03, 2016: Testing blood metabolites could help tailor cancer treatment 101
Jun 02, 2016: Curis Announces Presentations Related to Erivedge at 2016 ASCO Annual Meeting 103
Appendix 104
Methodology 104
About GlobalData 104
Contact Us 104
Disclaimer 104

List of Tables
Genentech Inc, Pharmaceuticals & Healthcare, Key Facts 2
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Genentech Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Genentech Inc, Deals By Therapy Area, 2011 to YTD 2017 11
Genentech Inc, Medical Devices Deals, 2011 to YTD 2017 13
Genentech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Genentech Acquires NanoPrint LM60 Microarrayer Platform From Arrayit 17
Epizyme Enters into Agreement with Genentech 18
Inovio Pharma Enters into Agreement with Genentech 19
Amunix Operating Enters into R&D Agreement with Genentech 20
BioNTech Enters into Agreement with Genentech 21
Gradalis Enters into Agreement with Genentech 22
G1 Therapeutics Enters into Agreement with Genentech 23
Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 24
Charles River Laboratories International Extends Agreement with Genentech 25
BioLineRx Enters into Agreement with Genentech 26
Epizyme Enters into Agreement with Genentech 27
Astex Pharma Enters into Agreement with Genentech 28
Clovis Oncology Enters into Agreement with Genentech 29
Janssen Research & Development Enters into Agreement with Genentech 30
Kite Pharma Enters into Agreement with Genentech 31
PeptiDream Enters into Agreement with Genentech 32
Corvus Pharma Expands its Agreement with Genentech 33
Immune Design Enters into Clinical Trial Collaboration with Genentech 34
WaferGen Bio-systems Enters into Research Agreement with Genentech 35
23andMe Partners with Genentech 36
Genentech Enters into Research Agreement with NewLink Genetics 37
Argenta Discovery Extends Drug Discovery Agreement With Genentech 38
Ascendis Pharma Enters Into Collaboration Agreement with Genentech 39
RQx Pharma Enters Into Drug Discovery Agreement With Genentech 40
Ensemble Therapeutics Enters Into Drug Discovery Agreement With Genentech 41
Constellation Pharma Enters Into Co-Development Agreement With Genentech 42
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 43
Galena Biopharma Enters Into Co-Development Agreement With The Henry M. Jackson Foundation And Genentech 44
Argenta Discovery Extends Drug Discovery Agreement With Genentech 46
Array BioPharma Enters Into Co-Development Agreement With Genentech 47
Plexxikon Enters Into Co-Promotion Agreement With Genentech 49
Dermira Enters into Licensing Agreement with F. Hoffmann-La Roche and Genentech for Lebrikizumab 50
Mylan Enters into Licensing Agreement with Genentech and Roche 52
Genentech Enters into Licensing Agreement with Novimmune 53
Genentech to Enter into Licensing Agreement with Hanmi Pharma 54
Denali Therapeutics Enters into Licensing Agreement with Genentech 55
Genentech Enters into Licensing Agreement with Nimbus Therapeutics 56
Genentech Expands Licensing Agreement with Arvinas 57
Phylogica Extends Licensing Agreement with Genentech 58
Genentech to Terminate its Licensing Agreement with NewLink Genetics for NLG919 59
Coherus BioSciences Enters into Licensing Agreement with Genentech 61
Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 62
Xenon Pharma Extends Licensing Agreement with Genentech 64
Novogen Enters into Licensing Agreement with Genentech for GDC-0084 65
Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 66
Genentech Enters into Licensing Agreement with Carmot Therapeutics 67
Genentech Enters into Licensing Agreement with Almac Discovery 68
Immunocore Enters Into Licensing And Research Agreement With Genentech For Cancer Drugs 69
Afraxis Enters Into Licensing Agreement With Genentech 70
AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 71
FORMA Therapeutics Enters Into Licensing Agreement With Genentech 73
Nerviano Medical Sciences Enters Into Licensing Agreement With Genentech 74
Spirogen Enters Into Licensing Agreement With Genentech 75
AMRI Enters Into Licensing Agreement With Genentech 76
Gilead Sciences Completes Acquisition Of Oceanside Clinical Plant From Genentech For US$28.3 Million 77
Noritsu Koki to Acquire 64.7% Stake in Genentech for USD27 Million 78
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 79
Genentech Inc, Key Competitors 80
Genentech Inc, Key Employees 81
Genentech Inc, Other Locations 82

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Genentech Inc-製薬・医療分野:企業M&A・提携分析(Genentech Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆